Novel portable hypothermic machine perfusion preservation device enhances cardiac viability of donated human hearts
Open Access
- 2 April 2024
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 11, 1376101
Abstract
Introduction: Heart transplant remains the gold standard treatment for patients with advanced heart failure. However, the list of patients waiting for a heart transplant continues to increase. We have developed a portable hypothermic oxygenated machine perfusion device, the VP.S ENCORE®, to extend the allowable preservation time. The purpose of this study was to test the efficacy of the VP.S. ENCORE® using deceased donors derived hearts.Methods: Hearts from brain-dead donors not utilized for transplant (n = 11) were offered for research from the Texas Organ Sharing Alliance (TOSA), South and Central Texas' Organ Procurement Organization (OPO) and were preserved in the VP.S ENCORE® for 4 (n = 2), 6 (n = 3), and 8 (n = 3) hours or were kept in static cold storage (SCS) (n = 3). After preservation, the hearts were placed in an isolated heart Langendorff model for reperfusion and evaluated for cardiac function.Results: The mean donor age was 37.82 ± 12.67 with the youngest donor being 19 and the oldest donor being 58 years old. SCS hearts mean weight gain (%) was −1.4 ± 2.77, while perfused at 4 h was 5.6 ± 6.04, perfused at 6 h 2.1 ± 6.04, and 8 h was 7.2 ± 10.76. Venous and arterial lactate concentrations were less than 2.0 mmol/L across all perfused hearts. Left ventricular contractility (+dPdT, mmHg/s) for 4 h (1,214 ± 1,064), 6 (1,565 ± 141.3), and 8 h (1,331 ± 403.6) were within the range of healthy human heart function. Thus, not significant as compared to the SCS group (1,597 ± 342.2). However, the left ventricular relaxation (mmHg/s) was significant in 6-hour perfused heart (p < 0.05) as compared to SCS. Gene expression analysis of inflammation markers (IL-6, IL-1β) showed no significant differences between SCS and perfused hearts, but a 6-hour perfusion led to a downregulated expression of these markers.Discussion: The results demonstrate that the VP.S ENCORE® device enhances cardiac viability and exhibits comparable cardiac function to a healthy heart. The implications of these findings suggest that the VP.S ENCORE® could introduce a new paradigm in the field of organ preservation, especially for marginal hearts.Keywords
This publication has 26 references indexed in Scilit:
- The international experience of in-situ recovery of the DCD heart: a multicentre retrospective observational studyeClinicalMedicine, 2023
- Donation After Circulatory Death: A New FrontierCurrent Cardiology Reports, 2022
- Results of Heart Transplants from Donation After Circulatory Death (DCD) Donors Using Thoraco-Abdominal Normothermic Regional Perfusion (TA-NRP) Compared to Donation After Brain Death (DBD)The Journal of Heart and Lung Transplantation, 2022
- Evaluation of donor heart for transplantationHeart Failure Reviews, 2022
- Cold ischemia >4 hours increases heart transplantation mortality. An analysis of the Spanish heart transplantation registryInternational Journal of Cardiology, 2020
- Donor heart and lung procurement: A consensus statementThe Journal of Heart and Lung Transplantation, 2020
- Metabolic characteristics of human hearts preserved for 12 hours by static storage, antegrade perfusion, or retrograde coronary sinus perfusionThe Journal of Thoracic and Cardiovascular Surgery, 2014
- RADIAL: A novel primary graft failure risk score in heart transplantationThe Journal of Heart and Lung Transplantation, 2011
- Myocardial oxygen consumption: the quest for its determinants and some clinical falloutJACC, 1999
- Biochemical Markers of Myocardial Injury During Cardiac OperationsThe Annals of Thoracic Surgery, 1997